Windward Bio AG is a Switzerland-based company primarily engaged in the biotechnology and biopharmaceutical industry. The Company focuses on the development of ultra-long-acting antibody medicines for immunological, respiratory, and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. Their key product is WIN378, which is a monoclonal antibody therapeutic that targets thymic stromal lymphopoietin (TSLP). It aims to reduce inflammation associated with respiratory diseases and provide longer dosing intervals for patients. The Company is also developing WIN027, a bispecific antibody targeting TSLP and interleukin-13 (IL-13) for immunological disorders.
公司代碼WWB
公司名稱Windward Bio AG
上市日期Nov 13, 2026
CEOSantarelli (Luca)
員工數量- -
證券類型Ordinary Share
年結日- -
公司地址Aeschenplatz 6
城市BASEL
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Switzerland
郵編4052
電話41615517575
網址https://windwardbio.com/
公司代碼WWB
上市日期Nov 13, 2026
CEOSantarelli (Luca)